ICAD INC. - COMMON STOCK

Health Canada Grants Device License for iCAD's ProFound Risk 2.0, Revolutionizing Breast Cancer Risk Via a 1-2 Year Assessment

16 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

iCAD Reports Financial Results for Second Quarter Ended June 30, 2023 

14 Aug 2023 16:01:00 By Nasdaq GlobeNewswire

iCAD and Google Health Expand Integration of Google’s AI Technology with iCAD’s ProFound Breast Health Suite for 2D Mammography for Use as Independent Reader

14 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

iCAD to Report Second Quarter 2023 Financial Results on August 14, 2023

31 Jul 2023 08:00:00 By Nasdaq GlobeNewswire

iCAD Signs Strategic Commercial Agreement with Radiology Partners, the Nation’s Largest Radiology Practice

18 Jul 2023 08:00:01 By Nasdaq GlobeNewswire

iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Feature Cleveland Clinic

12 Jul 2023 08:00:00 By Nasdaq GlobeNewswire

iCAD Offers ROI Analysis Based on Real-World Results from its ProFound Breast AI Suite at AHRA Annual Meeting

10 Jul 2023 08:00:00 By Nasdaq GlobeNewswire

iCAD’s ProFound AI Breast Suite Wins U.S. General Services Administration’s AI Healthcare Challenge Award

18 May 2023 08:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: ICAD INC. - COMMON STOCK

16 May 2023 09:59:31 By NetDania Notify

iCAD Reports Financial Results for First Quarter Ended March 31, 2023

15 May 2023 16:01:00 By Nasdaq GlobeNewswire

New Long-Term Real-World Research Confirms Xoft Skin eBx is as Safe and Effective as Mohs Surgery

11 May 2023 08:00:01 By Nasdaq GlobeNewswire

iCAD Showcases Breast AI Suite at Society of Breast Imaging Symposium, World’s Largest Breast Imaging Conference

03 May 2023 08:00:01 By Nasdaq GlobeNewswire

iCAD to Report First Quarter 2023 Financial Results on May 15, 2023

01 May 2023 08:00:02 By Nasdaq GlobeNewswire

iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Feature Boca Raton Regional Hospital

25 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

New and Real-World Clinical Evidence Confirms ProFound AI Increases Cancer Detection without Increasing the Rate of Recalls and Reveals Critical Clues to Inform Clinical Decisions

20 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

iCAD Strengthens Leadership Team with Appointment of Chief Financial Officer and New Senior Executives

17 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

ProFound AI Risk Outperforms Traditional, Widely-Accepted Breast Cancer Risk Models for Both Short-term and Long-term Risk Assessments

04 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

iCAD Reports Financial Results for Fourth Quarter ended December 31, 2022 and Year End

28 Mar 2023 16:01:00 By Nasdaq GlobeNewswire

iCAD’s Breast AI Suite Empowers Customers to Lead the Way in Support of FDA’s National Breast Density Reporting Standard

23 Mar 2023 08:00:01 By Nasdaq GlobeNewswire

iCAD Previews Fourth Quarter Financial Results, Full Report on March 28, 2023

13 Mar 2023 08:30:00 By Nasdaq GlobeNewswire